Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
CDC Analyzes Impediments to Viral Suppression in People With HIV

The CDC has reframed the HIV treatment cascade figures to highlight the various reasons why only 30 percent of Americans have a fully suppressed virus.

Published
03 December 2014
From
POZ
Leaving it late: why are people still dying from HIV in the UK?

People whose HIV infection is diagnosed late have a ten-fold increased risk of dying within the first year of diagnosis compared to those diagnosed early. And it’s estimated that someone who is diagnosed very late with HIV has a life expectancy at least 10 years shorter than someone who starts treatment earlier.

Published
02 December 2014
From
Public Health England blog
WHO: Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children

Recommendations for a public health approach - December 2014 supplement to the 2013 consolidated ARV guidelines.

Published
02 December 2014
From
World Health Organization
Does ‘treat’ always follow ‘test’? Why some people do not want HIV treatment

In South Africa, only one third of individuals living with HIV are actually on treatment. Treatment refusal has been identified as a phenomenon among people who are asymptomatic, however, factors driving refusal remain poorly understood.

Published
01 December 2014
From
UNAIDS Science Now
ARV supply issues cause treatment interruptions in a UK clinic

We have been told of ARV stock-outs that resulted in patients having to interrupt HIV medication due to problems in drug supply. It is difficult to understand why a UK clinic would allow problems to develop to the point that this happened not just once, but several times.

Published
01 December 2014
From
HIV i-Base
IRIS uncommon when ART starts in 96,000-person EuropeUS study

Immune reconstitution inflammatory syndrome (IRIS) appears to be rare when antiretroviral-naive adults in Europe and the United States start ART, with the possible exception of mycobacterial infections.

Published
01 December 2014
From
International AIDS Society
Only three in 10 Americans have HIV under control: government report

Just 30 percent of Americans living with HIV have the virus in check, putting others at risk of infection, U.S. health officials said yesterday. The report by the U.S. Centers for Disease Control and Prevention (CDC) found that 840,000 of the 1.2 million people infected with HIV in 2011 were not consistently taking anti-HIV drugs that keep the virus suppressed at very low levels.

Published
26 November 2014
From
Reuters
Looking to a New Era for Women's HIV Prevention: Zeda Rosenberg

Zeda Rosenberg, Chief Executive Offiver of the International Partnership for Microbicides, says: "While there is much progress to celebrate in HIV treatment and prevention, protecting women remains a major challenge. AIDS is the number-one killer of women ages 15 to 44 worldwide. Women are biologically more vulnerable to infection and face deep-rooted gender inequities that increase their risk. In sub-Saharan Africa, where the epidemic has taken the greatest toll, young women are at least twice as likely to contract HIV as young men."

Published
26 November 2014
From
Huffington Post
European Commission approves Rezolsta ® , a new once - daily , fixed - dose HIV therapy combining darunavir and cobicistat

Janssen-Cilag International NV (Janssen) today announced that the European Commission (EC) has approved the use of REZOLSTA ® (darunavir/cobicistat) in combination with other antiretroviral (ARV) medicinal products for the treatment of human immunodeficiency virus - 1 (HIV - 1) infection in adults aged 18 years or older. "REZOLSTA ® eliminates the need to take a boosting agent in a separate tablet with once - daily darunavir, reducing the pill burden for patients," said Christiane Moecklinghoff, M.D Ph.D, Medical Director, Virology, Janssen EMEA.

Published
25 November 2014
From
Janssen
START Study Could Change How We Look at HIV Treatment, and HIV Itself

Have you heard of the START (Strategic Timing of Antiretroviral Treatment) study? In my opinion, it is probably the most important study currently running. It generates strong views, both for and against initiating antiretroviral therapy early, but the results are likely to be surprising.

Published
25 November 2014
From
The Body

Filter by country